- Home
- RSF vs BYSI Comparison
RSF vs BYSI Comparison
Compare RSF & BYSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RSF | BYSI |
|---|---|---|
| Founded | 2016 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 59.1M | 58.4M |
| IPO Year | N/A | 2016 |
Fundamental Metrics
Financial Performance| Metric | RSF | BYSI |
|---|---|---|
| Price | $14.53 | $1.24 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 10.7K | ★ 25.7K |
| Earning Date | 01-01-0001 | 05-13-2026 |
| Dividend Yield | ★ 10.61% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.23 | $1.16 |
| 52 Week High | $15.07 | $2.44 |
Technical Indicators
Market Signals| Indicator | RSF | BYSI |
|---|---|---|
| Relative Strength Index (RSI) | 42.58 | 30.06 |
| Support Level | $14.52 | $1.18 |
| Resistance Level | $14.72 | $1.85 |
| Average True Range (ATR) | 0.08 | 0.13 |
| MACD | -0.01 | -0.05 |
| Stochastic Oscillator | 15.00 | 13.16 |
Price Performance
Historical ComparisonAbout RSF RiverNorth Capital and Income Fund
RiverNorth Capital and Income Fund is a diversified, closed-end management investment company. Its investment objective is to seek a high level of current income by investing in credit instruments, including a portfolio of securities of specialty finance and other financial companies.
About BYSI BeyondSpring Inc.
BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It operates in Plinabulin pipeline segment. Its first asset, Plinabulin is a novel brain-penetrant microtubule modulator with dendritic cell maturation and vasculature modulation mechanism, which has the potential to help mitigate acquired resistance from prior immune checkpoint inhibitors (ICI) treatment in cancer patients. It is a Selective Immunomodulating Microtubule-Binding Agent (SIMBA), which may provide multiple therapeutic opportunities.